What is InBios International?
InBios International, Inc. is a specialized entity focused on the design, development, and manufacturing of high-quality immunodiagnostics for infectious diseases. Their comprehensive product portfolio includes diagnostic tests for critical illnesses such as Chagas, Dengue, and COVID-19, with a global objective to enhance health outcomes. Serving clinical laboratories and healthcare providers, InBios prioritizes cost-effective and user-friendly diagnostic solutions. With a legacy spanning nearly 25 years, the company demonstrates a steadfast commitment to quality and a responsive approach to emerging infectious disease threats.
How much funding has InBios International raised?
InBios International has raised a total of $2M across 2 funding rounds:
Debt
$1M
Debt
$1M
Debt (2020): $1M with participation from PPP
Debt (2021): $1M led by PPP
Key Investors in InBios International
PPP
Public-Private Partnership
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for InBios International?
The recent major strategic investment positions InBios International for accelerated growth and innovation in the competitive diagnostics market. This capital infusion is expected to bolster research and development efforts, potentially expanding their test offerings and market reach. The company's established expertise in infectious disease diagnostics, coupled with this significant backing, suggests a strategic focus on scaling operations and solidifying its position as a key player in global health security. Future developments may include strategic partnerships and further product line enhancements to address evolving public health challenges.
See full InBios International company page
